Magnetic resonance elastography as a predictor of insufficient liver enhancement on gadoxetic acid-enhanced hepatocyte-phase magnetic resonance imaging in patients with type C hepatitis and child-pugh class a disease

Investigative Radiology

Volumn 47, Issue 10, 2012, Pages 566-570

  Motosugi, Utaroh ^a   Ichikawa, Tomoaki ^a   Muhi, Ali ^a,b   Sano, Katsuhiro ^a   Morisaka, Hiroyuki ^a   Ichikawa, Shintaro ^a   Araki, Tsutomu ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b AL MUTHANNA UNIVERSITY   (Iraq)

Author keywords

cirrhosis; gadoxetic acid; liver; magnetic resonance elastography; magnetic resonance imaging

Indexed keywords

ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GADOXETIC ACID;

ADULT; ARTICLE; CONTRAST ENHANCEMENT; DISEASE SEVERITY; ELASTOGRAPHY; FEMALE; HEPATITIS C; HUMAN; LABORATORY TEST; LIVER CELL; LIVER FIBROSIS; MAGNETIC RESONANCE ELASTOGRAPHY; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SPLEEN; THROMBOCYTE COUNT;

EID: 84866324646     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e318260ac9e     Document Type: Article

References (39)

1. Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodiumYenhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocel-lular carcinoma and chronic liver disease. Invest Radiol. 2010;45:133-141.
2. Sano K, Ichikawa T, Motosugi U, et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acidYenhanced MR imaging. Radiology. 2011;261:834-844.
3. Muhi A, Ichikawa T, Motosugi U, et al. Diagnosis of colorectal hepatic me-tastases: comparison of contrast-enhanced CT, contrast-enhanced US, super-paramagnetic iron oxide-enhanced MRI, and gadoxetic acidYenhanced MRI. J Magn Reson Imaging. 2011;34:326-335.
4. Rhee H, Kim MJ, Park YN, et al. Gadoxetic acidYenhanced MRI findings of early hepatocellular carcinoma as defined by new histologic criteria. J Magn Reson Imaging. 2012;35:393-398.
5. Kim YK, Kim CS, Han YM, et al. Detection of small hepatocellular carcinoma: intraindividual comparison of gadoxetic acidYenhanced MRI at 3.0 and 1.5 T. Invest Radiol. 2011;46:383-389.
6. Kim YK, Lee MW, Lee WJ, et al. Diagnostic accuracy and sensitivity of diffusion-weighted and of gadoxetic acidYenhanced 3-T MR imaging alone or in combination in the detection of small liver metastasis (G/= 1.5 cm in diameter). Invest Radiol. 2012;47:159-166.
7. Golfieri R, Renzulli M, Lucidi V, et al. Contribution of the hepatobiliary phase of Gd-EOB-DTPAYenhanced MRI to dynamic MRI in the detection of hypo-vascular small (G/= 2 cm) HCC in cirrhosis. Eur Radiol. 2011;21:1233-1242.
8. Sun HY, Lee JM, Shin CI, et al. Gadoxetic acidYenhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (G or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepato-biliary phase imaging. Invest Radiol. 2010;45:96-103.
9. Motosugi U, Ichikawa T, Sou H, et al. Distinguishing hypervascular pseudo-lesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acidYenhanced MR imaging. Radiology. 2010;256:151-158.
10. Kim YK, Kim CS, Han YM, et al. Detection of small hepatocellular carcinoma: can gadoxetic acidYenhanced magnetic resonance imaging replace combining gadopentetate dimeglumineYenhanced and superparamagnetic iron oxi-deYenhanced magnetic resonance imaging? Invest Radiol. 2010;45:740-746.
11. Hwang J, Kim SH, Kim YS, et al. Gadoxetic acidYenhanced MRI versus multiphase multidetector row computed tomography for evaluating the viable tumor of hepatocellular carcinomas treated with image-guided tumor therapy. J Magn Reson Imaging. 2010;32:629-638.
12. Ahn SS, Kim MJ, Lim JS, et al. Added value of gadoxetic acidYenhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology. 2010;255:459-466.
13. Motosugi U, Ichikawa T, Sou H, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging. 2009;30:1042-1046.
14. Shimizu J, Dono K, Gotoh M, et al. Evaluation of regional liver function by gadolinium-EOB-DTPAYenhanced MR imaging. Dig Dis Sci. 1999;44:1330-1337. (Pubitemid 29404293)
15. Tsuda N, Matsui O. Cirrhotic rat liver: reference to transporter activity and morphologic changes in bile canaliculiYgadoxetic acidYenhanced MR imaging. Radiology. 2010;256:767-773.
16. Watanabe H, Kanematsu M, Goshima S, et al. Staging hepatic fibrosis: comparison of gadoxetate disodiumYenhanced and diffusion-weighted MR imagi-ngVpreliminary observations. Radiology. 2011;259:142-150.
17. Yin M, Talwalkar JA, Glaser KJ, et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol. 2007;5:1207-1213.e2.
18. Rouviere O, Yin M, Dresner MA, et al. MR elastography of the liver: preliminary results. Radiology. 2006;240:440-448. (Pubitemid 44098640)
19. Motosugi U, Ichikawa T, Sou H, et al. Magnetic resonance elastography of the liver: preliminary results and estimation of interrater reliability. Jpn J Radiol. 2010;28:623-627.
20. Asbach P, Klatt D, Schlosser B, et al. Viscoelasticity-based staging of hepatic fibrosis with multifrequency MR elastography. Radiology. 2010;257:80-86.
21. Huwart L, Sempoux C, Salameh N, et al. Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index. Radiology. 2007;245:458-466. (Pubitemid 47612527)
22. Motosugi U, Ichikawa T, Tominaga L, et al. Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: is it possible to shorten the examination time? Eur Radiol. 2009;19:2623-2629.
23. Glaser KJ, Felmlee JP, Manduca A, et al. Shear stiffness estimation using intravoxel phase dispersion in magnetic resonance elastography. Magn Reson Med. 2003;50:1256-1265. (Pubitemid 37494027)
24. Muthupillai R, Lomas DJ, Rossman PJ, et al. Magnetic resonance elastography by direct visualization of propagating acoustic strain waves. Science. 1995;269: 1854-1857.
25. Manduca A, Oliphant TE, Dresner MA, et al. Magnetic resonance elastography: non-invasive mapping of tissue elasticity. Med Image Anal. 2001;5:237-254. (Pubitemid 35282809)
26. Wells RG. The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis. J Clin Gastroenterol. 2005;39:S158YS161.
27. Huwart L, Sempoux C, Vicaut E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology. 2008;135:32-40. (Pubitemid 351899024)
28. Hines CD, Bley TA, Lindstrom MJ, et al. Repeatability of magnetic resonance elastography for quantification of hepatic stiffness. J Magn Reson Imaging. 2010;31:725-731.
29. Shire NJ, Yin M, Chen J, et al. Test-retest repeatability of MR elastography for noninvasive liver fibrosis assessment in hepatitis C. J Magn Reson Imaging. 2011;34:947-955.
30. Anaparthy R, Talwalkar JA, Yin M, et al. Liver stiffness measurement by magnetic resonance elastography is not associated with developing hepatocel-lular carcinoma in subjects with compensated cirrhosis. Aliment Pharmacol Ther. 2011;34:83-91.
31. Tsuboyama T, Onishi H, Kim T, et al. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acidYenhanced MR imagingVcorrelation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology. 2010;255:824-833.
32. Tanimoto A, Lee JM, Murakami T, et al. Consensus report of the 2nd International Forum for Liver MRI. Eur Radiol. 2009;19(suppl 5):S975-S989.
33. Gschwend S, Ebert W, Schultze-Mosgau M, et al. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. Invest Radiol. 2011;46:556-566.
34. Motosugi U, Ichikawa T, Sano K, et al. Double-dose gadoxetic acidYenhanced magnetic resonance imaging in patients with chronic liver disease. Invest Radiol. 2011;46:141-145.
35. Haradome H, Grazioli L, Tsunoo M, et al. Can MR fluoroscopic triggering technique and slow rate injection provide appropriate arterial phase images with reducing artifactson gadoxetic acidYDTPA (Gd-EOB-DTPA)Yenhanced hepatic MR imaging? J Magn Reson Imaging. 2010;32:334-340.
36. Doo KW, Lee CH, Choi JW, et al. "Pseudo washout"sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervas-cular tumor. AJR Am J Roentgenol. 2009;193:W490-W496.
37. Motosugi U, Ichikawa T, Onohara K, et al. Distinguishing hepatic metastasis from hemangioma using gadoxetic acidYenhanced magnetic resonance imaging. Invest Radiol. 2011;46:359-365.
38. Nakamura S, Awai K, Utsunomiya D, et al. Chronological evaluation of liver enhancement in patients with chronicliver disease at Gd-EOB-DTPAYenhanced 3-T MR imaging: does liver function correlate with enhancement? Jpn J Radiol. 2012;30:25-33.
39. Moriyama Y, Saito S, Kobayashi S, et al. Evaluation of concanavalin AYinduced acute liver injury in rats using an empirical mathematical model and dynamic contrast-enhanced MR imaging with Gd-EOB-DTPA. Magn Reson Med Sci. 2012;11:53-60.